NO992116L - Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner - Google Patents

Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner

Info

Publication number
NO992116L
NO992116L NO992116A NO992116A NO992116L NO 992116 L NO992116 L NO 992116L NO 992116 A NO992116 A NO 992116A NO 992116 A NO992116 A NO 992116A NO 992116 L NO992116 L NO 992116L
Authority
NO
Norway
Prior art keywords
therapeutic
cytokines
diagnostic agents
signal transduction
present
Prior art date
Application number
NO992116A
Other languages
English (en)
Norwegian (no)
Other versions
NO992116D0 (no
Inventor
Douglas J Hilton
Warren S Alexander
Elizabeth M Viney
Tracy A Willson
Rachael T Richardson
Robyn Starr
Sandra E Nicholson
Donald Metcalf
Nicos A Nicola
Original Assignee
Inst Medical W & E Hall
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPO3384A external-priority patent/AUPO338496A0/en
Priority claimed from AUPO5117A external-priority patent/AUPO511797A0/en
Application filed by Inst Medical W & E Hall filed Critical Inst Medical W & E Hall
Publication of NO992116D0 publication Critical patent/NO992116D0/no
Publication of NO992116L publication Critical patent/NO992116L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO992116A 1996-11-01 1999-04-30 Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner NO992116L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO3384A AUPO338496A0 (en) 1996-11-01 1996-11-01 Therapeutic and diagnostic agents
AUPO5117A AUPO511797A0 (en) 1997-02-14 1997-02-14 Therapeutic and diagnostic agents-II
PCT/AU1997/000729 WO1998020023A1 (en) 1996-11-01 1997-10-31 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines

Publications (2)

Publication Number Publication Date
NO992116D0 NO992116D0 (no) 1999-04-30
NO992116L true NO992116L (no) 1999-06-29

Family

ID=25645307

Family Applications (1)

Application Number Title Priority Date Filing Date
NO992116A NO992116L (no) 1996-11-01 1999-04-30 Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner

Country Status (13)

Country Link
US (1) US20080166730A1 (de)
EP (2) EP1975234A2 (de)
JP (2) JP2001502183A (de)
KR (2) KR100719080B1 (de)
CN (2) CN1253565A (de)
AT (1) ATE398136T1 (de)
CA (1) CA2270171A1 (de)
DE (1) DE69738767D1 (de)
DK (1) DK0948522T3 (de)
ES (1) ES2308785T3 (de)
GB (1) GB2331753A (de)
NO (1) NO992116L (de)
WO (1) WO1998020023A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495518B1 (en) 1994-06-13 2002-12-17 Vanderbilt University Method for importing biologically active molecules into cells
CA2230986A1 (en) * 1997-05-07 1998-11-07 Smithkline Beecham Corporation Epo primary response gene 1, eprg1
AU8484698A (en) * 1997-07-18 1999-02-10 Schering Corporation Suppressors of cytokine signaling socs16; related reagents
JP2001508312A (ja) * 1997-11-03 2001-06-26 インサイト・ファーマスーティカルズ・インコーポレイテッド サイトカインシグナリングのサプレッサ
AU2668699A (en) * 1998-02-11 1999-08-30 Beth Israel Deaconess Medical Center Methods and compositions for modulating leptin activity
EP0953636A3 (de) * 1998-03-23 2000-03-29 Smithkline Beecham Plc Cytokin-Signal Regulator
EP1064368A1 (de) * 1998-03-23 2001-01-03 Smithkline Beecham Plc Suppressoren des cytokinsignals
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
WO1999061614A2 (en) * 1998-05-28 1999-12-02 Incyte Pharmaceuticals, Inc. Human socs proteins
SE9803398D0 (sv) * 1998-10-06 1998-10-06 Sahltech Ab "New use"
WO2000037636A1 (en) * 1998-12-21 2000-06-29 The Walter And Eliza Hall Institute Of Medical Research Socs-box containing peptides
WO2000063357A2 (en) * 1999-04-20 2000-10-26 Beth Israel Deaconess Medical Center Methods and compositions for modulating ciliary neurotrophic factor activity
US6541244B1 (en) 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
WO2001035732A1 (en) * 1999-11-16 2001-05-25 The Walter And Eliza Hall Institute Of Medical Research An animal model for studying hormone signalling and method of modulating the signalling
AU784277B2 (en) * 1999-11-16 2006-03-02 Walter And Eliza Hall Institute Of Medical Research, The An animal model for studying hormone signalling and method of modulating the signalling
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
EP1330156A4 (de) * 2000-10-09 2006-09-13 Amrad Operations Pty Ltd Modulation der cytokin- oder hormonsignalleitung bei einem tier, wobei die expression der socs-sequenz bei diesem tier hinaufreguliert wird
GB2373502A (en) * 2000-11-08 2002-09-25 Smithkline Beecham Corp Suppressor of cytokine signalling 4 (SOCS4)
EP1341913A2 (de) * 2000-12-14 2003-09-10 PHARMACIA & UPJOHN COMPANY Socs (suppressor der cytokin signalierung)
AUPR556601A0 (en) * 2001-06-08 2001-07-12 Ludwig Institute For Cancer Research Therapeutic and diagnostic molecules - II
JPWO2003072778A1 (ja) * 2002-02-27 2005-06-23 株式会社ジェノックス創薬研究所 アレルギー性疾患の検査方法
US8420096B2 (en) 2004-03-04 2013-04-16 Vanderbilt University Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling
JP2005312364A (ja) * 2004-04-28 2005-11-10 Mitsuo Itakura 糖尿病治療剤スクリーニング方法
WO2006088010A1 (ja) * 2005-02-15 2006-08-24 Toagosei Co., Ltd. 抗菌ペプチド及びその利用
EP2427210A4 (de) * 2009-05-08 2012-10-24 Inst Medical W & E Hall Modulation der bindung von induzierbarer stickoxidsynthase (inos) an spry-domain-haltige socs-box-peptide (ssb)
KR101124622B1 (ko) * 2009-10-26 2012-03-19 한국생명공학연구원 Ｓｏｃｓ２ 유전자의 발현을 조절하여 자연 살해 세포를 활성화시키는 방법
JP2019505498A (ja) * 2015-12-16 2019-02-28 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4420782C1 (de) * 1994-06-15 1995-08-17 Fluegge Ulf Ingo Prof Dr DNA-Sequenz, kodierend einen 2-Oxoglutarat/Malat-Translokator, Plasmide, Bakterien, Hefen und Pflanzen enthaltend diesen Transporter
US4018653A (en) 1971-10-29 1977-04-19 U.S. Packaging Corporation Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4424279A (en) 1982-08-12 1984-01-03 Quidel Rapid plunger immunoassay method and apparatus
JPH07291996A (ja) * 1994-03-01 1995-11-07 Yuu Honshiyo ヒトにおけるプログラムされた細胞死に関連したポリペプチド、それをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのポリペプチドまたはその抗体を含有する薬学的組成物
EP0832117A1 (de) * 1995-06-05 1998-04-01 The Trustees Of Dartmouth College Genexpression, stimuliert durch liganden
AU4723797A (en) * 1997-01-10 1998-08-03 Tadamitsu Kishimoto Novel stat function-regulatory protein
AU8484698A (en) * 1997-07-18 1999-02-10 Schering Corporation Suppressors of cytokine signaling socs16; related reagents

Also Published As

Publication number Publication date
CN1253565A (zh) 2000-05-17
ES2308785T3 (es) 2008-12-01
EP1975234A2 (de) 2008-10-01
EP0948522B1 (de) 2008-06-11
EP0948522A4 (de) 2001-09-19
KR100719080B1 (ko) 2007-05-16
CA2270171A1 (en) 1998-05-14
ATE398136T1 (de) 2008-07-15
US20080166730A1 (en) 2008-07-10
WO1998020023A1 (en) 1998-05-14
CN101280305A (zh) 2008-10-08
GB2331753A (en) 1999-06-02
GB9905020D0 (en) 1999-04-28
KR20000053017A (ko) 2000-08-25
DK0948522T3 (da) 2008-09-22
JP2001502183A (ja) 2001-02-20
EP0948522A1 (de) 1999-10-13
JP2009060903A (ja) 2009-03-26
NO992116D0 (no) 1999-04-30
KR20060053007A (ko) 2006-05-19
DE69738767D1 (de) 2008-07-24

Similar Documents

Publication Publication Date Title
NO992116D0 (no) Terapeutiske og diagnostiske midler som er i stand til Õ modulere responderbarhet overfor cytokiner
ATE413386T1 (de) Ppar-gamma modulatoren
DK0960127T3 (da) Isoleret dimert fibroblastaktiverende protein-alfa og anvendelser deraf
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
DK0850307T3 (da) Alkalifile og termofile mikroorganismer og enzymer, der opnås derfra
DK0804163T3 (da) Forbedret fremgangsmåde til stabilisering af biologiske stoffer under tørring og efterfølgende opbevaring samt præparater deraf
DE69832293D1 (de) Zubereitungen zur abgabe von negativ geladenen molekülen
ATE234092T1 (de) 2-alkylpyrrolidine
ATE233561T1 (de) Imidazolverbindungen
DE69435218D1 (de) Regulation der Genexpression von bcl-2
ATE292975T1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
EA200700469A1 (ru) Экспрессионная кассета и вектор для временной или постоянной экспрессии экзогенных молекул
MY107573A (en) 2,4- and 2, 5-substituted pyridine-n-oxides, processes for their preparation and their use.
BG101002A (bg) Заместени арилалкилтио-алкилтиопиридини и използване за борба с бактерии от рода helicobacter
DK1178726T3 (da) Vandig opløsning til konservering af væv og organer
DK0556322T3 (da) Aminosulfonylurinstof-ACAT-inhibitorer
DE60327936D1 (de) Modulatoren von ship-1
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
IS7154A (is) Bv8 kjarnsýrur og fjölpeptíð með mítósu-valdandi verkun
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
DE3787954D1 (de) Verwendung von 5-(Subst. Phenyl)- Oxazolidinonderivaten zur Behandlung von Depressionen.
ATE255594T1 (de) Hepatitis b inhibitoren
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung